Abstract
Background In the first weeks of the COVID-19 epidemic in Belgium, a repetitive national serum collection was set up to monitor age-related exposure through emerging SARS-CoV-2 antibodies. First objective was to estimate the baseline seroprevalence and seroincidence using serial survey data that covered the start of a national lock-down period installed soon after the epidemic was recognized.
Methods A prospective serial cross-sectional seroprevalence study, stratified by age, sex and region, started with two collections in April 2020. In residual sera taken outside hospitals and collected by diagnostic laboratories, IgG antibodies against S1 proteins of SARS-CoV-2 were measured with a semi-quantitative commercial ELISA. Seropositivity (cumulative, by age category and sex) and seroincidence over a 3 weeks period were estimated for the Belgian population.
Findings In the first collection, IgG antibodies were detected in 100 out of 3910 samples, whereas in the second collection 193 out of 3391 samples were IgG positive. The weighted overall seroprevalence increased from 2·9% (95% CI 2·3 to 3·6) to 6·0% (95% CI 5·1 to 7·1), reflected in a seroincidence estimate of 3·1% (95% CI 1·9 to 4·3). Age-specific seroprevalence significantly increased in the age categories 20-30, 80-90 and ≥90. No significant sex effect was observed.
Interpretation During the start of epidemic mitigation by lockdown, a small but increasing fraction of the Belgian population showed serologically detectable signs of exposure to SARS-CoV-2.
Funding This independent researcher-initiated study acknowledges financial support from the Antwerp University Fund, the Flemish Research Fund, and European Horizon 2020.
Evidence before this study This is the first study reporting seroprevalence and seroincidence of IgG against SARS-CoV-2 in the Belgian population. Worldwide, PCR tests are being performed to identify mainly sick people suffering from COVID-19. However, seroprevalence studies are important and feasible to study the proportion of the population that has already been in contact with the virus, which helps to understand the likelihood of asymptomatic infections or infections with mild symptoms.
From 11 March to 11 May, updates on the COVID-19 pandemic by the World Health Organisation as well as bulletins from the Belgian Scientific Institute for Public Health, Sciensano, were consulted daily. Press releases from all over the world were monitored during that period. Google, PubMed as well as the pre-print server medrxiv were consulted by searching the terms “seroprevalence SARS-CoV-2” and “COVID-19”,
Added value of this study This study reports that seroprevalence increased in Belgium from 2·9% (95% CI 2·3 to 3·6) to 6·0% (95% CI 5·1 to 7·1) over a period of 3 weeks during lockdown (30 March-5 April 2020 & 20-26 April 2020) with seroincidence estimate of 3·1% (95% CI 1·9 to 4·3). Moreover, a significant increase in seroprevalence in the age categories 20-30 and ≥80 and within each sex were reported.
Implications of all the available evidence Seroprevalences worldwide indicate that an increasing fraction of the population has already been exposed to SARS-CoV-2. The continuous monitoring of seroprevalences is valuable to calibrate the response to the epidemic and to guide policy makers to control the epidemic wave and potential future waves and to avoid a deconfinement strategy leading to a rebound. However, it seems likely that natural exposure during this pandemic might not soon deliver the required level of herd immunity and there will be a substantial need for mass vaccination programmes to save time and lives.
Competing Interest Statement
All authors have completed the Unified Competing Interest form available at www.icmje.org/coi_disclosure.pdf and declare: support from research grants from GSK Biologicals, Pfizer, SANOFI, Merck, Themis, Osivax, J&J and Abbott and grants from The Bill & Melinda Gates Foundation, PATH, Flemish Government and European Union, outside the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work received funding from the European Unions Horizon 2020 research and innovation program project EpiPose (No 101003688), the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation program (grant agreement 682540 TransMID), the Flemish Research Fund (FWO 1150017N) and from The Antwerp University Fund; which is a community of donors who contribute to research and education with their personal commitment through a donation, gift, bequest or through academic chairs. We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study: Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont), Declerck Klinisch Laboratorium (Ardooie), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien), Medisch labo Bruyland (Kortrijk), Synlab (Luik).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Ethics Committee of the University Hospital Antwerp-University of Antwerp on March 30, 2020 (ref 20/13/158; Belgian Number B3002020000047) and agreed with inclusion without informed consent, on the condition of the samples being collected unlinked and anonymously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors are willing to share original data on request.
